This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Phibro (PAHC) Stock Now
by Zacks Equity Research
Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.
Why Is Phibro (PAHC) Up 8.5% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down
by Zacks Equity Research
Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.
Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes
by Zacks Equity Research
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
Why Is Phibro (PAHC) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for September 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.
Phibro Animal Sees Crucial Progress in ASF Vaccine Development
by Zacks Equity Research
The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.
Phibro (PAHC) Up 3.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.
Phibro Animal Solid on Global Prospects, Currency Woes Ail
by Zacks Equity Research
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
Phibro (PAHC) Down 6.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
Moving Average Crossover Alert: Phibro Animal Health Corporation
by Zacks Equity Research
Phibro Animal Health Corporation could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Phibro (PAHC) Down 14.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Phibro Animal Health (PAHC)
by Zacks Equity Research
Phibro Animal Health (PAHC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
Why Is Phibro (PAHC) Down 13.3% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in Phibro (PAHC) Right Now
by Zacks Equity Research
Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.
Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.
Why Is Phibro Animal (PAHC) Up 10.7% Since Its Last Earnings Report?
by Zacks Equity Research
Phibro Animal (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q3.
Zacks.com featured highlights include: Archer Daniels, Phibro Animal, NEXEO, Western Digital and Fortinet
by Zacks Equity Research
Zacks.com featured highlights include: Archer Daniels, Phibro Animal, NEXEO, Western Digital and Fortinet
5 Stocks Near 52-Week High: Is More Upside Left?
by Zacks Equity Research
These stocks have passed through a screen we ran to find those that are trading near their 52-week high levels and still have plenty of upside left.
Here's Why Phibro Animal Health is Worth a Buy Right Now
by Zacks Equity Research
Phibro Animal Health (PAHC) continues to boost investor confidence on the back of sturdy segmental performances.